Tag: retinitis pigmentosa
IDT Australia secures $3.2M manufacturing contract for investigational eye therapy
ASX-listed IDT Australia Limited has been awarded a five-year contract valued at $3.2 million for the manufacture of NPI-001 tablets, an investigational treatment for retinitis pigmentosa (RP), a degenerative eye disease that can lead to vision loss.
Featured Article
What spending reveals about downstream consumer demand for manufactured goods
For manufacturers supplying consumer-facing markets, understanding demand conditions has become increasingly important in an environment shaped by cautious spending, rising costs and intense competition.
